US Patent Issued to Incyte on Sept. 30 for "Tricyclic heterocycles as FGFR inhibitors" (Delaware, Pennsylvania Inventors)

ALEXANDRIA, Va., Sept. 30 -- United States Patent no. 12,428,420, issued on Sept. 30, was assigned to Incyte Corp. (Wilmington, Del.).

"Tricyclic heterocycles as FGFR inhibitors" was invented by Robert Swyka (Wilmington, Del.), Evan Styduhar (Claymont, Del.), Xin Li (Claymont, Del.), Oleg Vechorkin (Wilmington, Del.) and Wenqing Yao (Chadds Ford, Pa.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to tricyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer."

The patent was filed on June 8, 2022, under Application No. 17/835,330.

*For further information...